Skip to content

The effect of oral care and honey mouthwash on the mucositis

The effect of oral care program and honey mouthwash on mucositis, weight loss and quality of life of patients with Acute Myeloid leukemia undergoing chemotherapy: A Randomaized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015121419919N7
Enrollment
51
Registered
2016-02-01
Start date
2015-12-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucositis. (Oral mucositis (ulcerative

Interventions

Intervention 1: In oral care intervention program involves the use of a soft toothbrush twice a day, flossing once, three times a day before and after every meal and before bed-time of normal saline (
Prevention
In oral care intervention program involves the use of a soft toothbrush twice a day, flossing once, three times a day before and after every meal and before bed-time of normal saline (60 mL for 30 sec
The intervention group that receive honey mouthwash, a solution of a big tablespoon of honey that will be solved in mild water gurgled and keep in the mouth that can involve the entire surface of the
In the control group patients only receive routine care and intervention will be done.

Sponsors

Deputy of Research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Adults (over 18 years) undergoing chemotherapy with AML is the first candidate for chemotherapy. Not using smoking, hookah, tobacco, opioid and alcohol, do not receive radiotherapy and treated with induction (3+7 regimen) Exclusion criteria: discharged against medical advice or death during study, lack of patient cooperation, having thrombocytopenia (platelet count less than 20,000 per m m3), previous radiotherapy and chemotherapy in patients, promyelocytic leukemia AML m3 for treatment of arsenic (if the patient along with arsenic regimen 3+7 receive will be part of the intervention group)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mucositis. Timepoint: Once before and four after the intervention (at the end of the first week, second, third and fourth). Method of measurement: WHO scale.

Secondary

MeasureTime frame
Quality of life. Timepoint: Once before and once at the end of the fourth week after intervention. Method of measurement: EORTC QLQ – C30 . V .3 questionnaire.;Weight. Timepoint: Once before and four after the intervention (at the end of the first week, second, third and fourth). Method of measurement: Balance.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo khanjani

Tabriz University of Medical Sciences

arezookhanjani68@ gmail.com+98 41 3347 7379

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026